SIGLEC1,SN (Sialoadhesin) or CD169 is a single-pass type I transmembrane protein belonging to the sialic acid binding Ig-like lectin (SIGLEC) family in the immunoglobulin superfamily (IgSF). SIGLECs are characterized by an N-terminal Ig-like V-type (IgV)domain that mediates sialic acid binding, followed by varying numbers (2 to 17) of Ig-like C2-type (IgC2) domains in the extracellular region, a transmembrane region, and a cytoplasmic tail with intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM). They can be classified into two subgroups: Siglecs-1, -2, and -4 subgroup, and a Siglec-3/CD33-related subgroup (Siglecs-3, and -5 through -13), defined by sequence similarity and clustered gene localization. SIGLECs are widely expressed on hematopoietic cells, often in a cell-type-specific manner.  SIGLEC1 contains 16 IgC2 domains and acts as an endocytic receptor mediating clathrin dependent endocytosis.  SIGLEC1 is a macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells.  SIGLEC1 preferentially binds to alpha-2,3-linked sialic acid and  SPN/CD43 on T-cells. SIGLEC1 may also play a role in hemopoiesis.  Alternative splicing produces a transcript variant encoding a soluble isoform of SIGLEC1.

SIGLEC1,SN (Sialoadhesin) or CD169 is a single-pass type I transmembrane protein belonging to the sialic acid binding Ig-like lectin (SIGLEC) family in the immunoglobulin superfamily (IgSF). SIGLECs are characterized by an N-terminal Ig-like V-type (IgV)domain that mediates sialic acid binding, followed by varying numbers (2 to 17) of Ig-like C2-type (IgC2) domains in the extracellular region, a transmembrane region, and a cytoplasmic tail with intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM). They can be classified into two subgroups: Siglecs-1, -2, and -4 subgroup, and a Siglec-3/CD33-related subgroup (Siglecs-3, and -5 through -13), defined by sequence similarity and clustered gene localization. SIGLECs are widely expressed on hematopoietic cells, often in a cell-type-specific manner.  SIGLEC1 contains 16 IgC2 domains and acts as an endocytic receptor mediating clathrin dependent endocytosis.  SIGLEC1 is a macrophage-restricted adhesion molecule that mediates sialic-acid dependent binding to lymphocytes, including granulocytes, monocytes, natural killer cells, B-cells and CD8 T-cells.  SIGLEC1 preferentially binds to alpha-2,3-linked sialic acid and  SPN/CD43 on T-cells. SIGLEC1 may also play a role in hemopoiesis.  Alternative splicing produces a transcript variant encoding a soluble isoform of SIGLEC1.

 

Product Details

 

Gene Symbol: SIGLEC1; SN; CD169; SIGLEC-1; Sialoadhesin; dJ1009E24.1

 

NCBI Gene ID: 6614

 

Uniprot Entry: Q9BZZ2

 

Construct Details: Full length human SIGLEC1 gene is subcloned into the Lentiviral expression vector pLTC with an upstream CMV promoter and with or without an antibiotics selection marker, which can be used for both transient and stable expression in mammalian cells.  It can be co-transfected with the LentiPAK DNA mix (SKU# LP-001) into HEK293 cells to produce high titer lentiviral particles.

 

Vector Type: pLTC or pLTC-Marker (see the vector map above)

 

Gene Insert Size: 5130 bp  

 

Gene Insert Sequence:  

ATGGGCTTCTTGCCCAAGCTTCTCCTCCTGGCCTCATTCTTCCCAGCAGGCCAGGCCTCATGGGGCGTCT

CCAGTCCCCAGGACGTGCAGGGTGTGAAGGGGTCTTGCCTGCTTATCCCCTGCATCTTCAGCTTCCCTGC

CGACGTGGAGGTGCCCGACGGCATCACGGCCATCTGGTACTACGACTACTCGGGCCAGCGGCAGGTGGTG

AGCCACTCGGCGGACCCCAAGCTGGTGGAGGCCCGCTTCCGCGGCCGCACCGAGTTCATGGGGAACCCCG

AGCACAGGGTGTGCAACCTGCTGCTGAAGGACCTGCAGCCCGAGGACTCTGGTTCCTACAACTTCCGCTT

CGAGATCAGTGAGGTCAACCGCTGGTCAGATGTGAAAGGCACCTTGGTCACAGTAACAGAGGAGCCCAGG

GTGCCCACCATTGCCTCCCCGGTGGAGCTTCTCGAGGGCACAGAGGTGGACTTCAACTGCTCCACTCCCT

ACGTATGCCTGCAGGAGCAGGTCAGACTGCAGTGGCAAGGCCAGGACCCTGCTCGCTCTGTCACCTTCAA

CAGCCAGAAGTTTGAGCCCACCGGCGTCGGCCACCTGGAGACCCTCCACATGGCCATGTCCTGGCAGGAC

CACGGCCGGATCCTGCGCTGCCAGCTCTCCGTGGCCAATCACAGGGCTCAGAGCGAGATTCACCTCCAAG

TGAAGTATGCCCCCAAGGGTGTGAAGATCCTCCTCAGCCCCTCGGGGAGGAACATCCTTCCAGGTGAGCT

GGTCACACTCACCTGCCAGGTGAACAGCAGCTACCCTGCAGTCAGTTCCATTAAGTGGCTCAAGGATGGG

GTACGCCTCCAAACCAAGACTGGTGTGCTGCACCTGCCCCAGGCAGCCTGGAGCGATGCTGGCGTCTACA

CCTGCCAAGCTGAGAACGGCGTGGGCTCTTTGGTCTCACCCCCCATCAGCCTCCACATCTTCATGGCTGA

GGTCCAGGTGAGCCCAGCAGGTCCCATCCTGGAGAACCAGACAGTGACACTAGTCTGCAACACACCCAAT

GAGGCACCCAGTGATCTCCGCTACAGCTGGTACAAGAACCATGTCCTGCTGGAGGATGCCCACTCCCATA

CCCTCCGGCTGCACTTGGCCACTAGGGCTGATACTGGCTTCTACTTCTGTGAGGTGCAGAACGTCCATGG

CAGCGAGCGCTCGGGCCCTGTCAGCGTGGTAGTCAACCACCCGCCTCTCACTCCAGTCCTGACAGCCTTC

CTGGAGACCCAGGCGGGACTTGTGGGCATCCTTCACTGCTCTGTGGTCAGTGAGCCCCTGGCCACACTGG

TGCTGTCACATGGGGGTCATATCCTGGCCTCCACCTCCGGGGACAGTGATCACAGCCCACGCTTCAGTGG

TACCTCTGGTCCCAACTCCCTGCGCCTGGAGATCCGAGACCTGGAGGAAACTGACAGTGGGGAGTACAAG

TGCTCAGCCACCAACTCCCTTGGAAATGCAACCTCCACCCTGGACTTCCATGCCAATGCCGCCCGTCTCC

TCATCAGCCCGGCAGCCGAGGTGGTGGAAGGACAGGCAGTGACACTGAGCTGCAGAAGCGGCCTAAGCCC

CACACCTGATGCCCGCTTCTCCTGGTACCTGAATGGAGCCCTGCTTCACGAGGGTCCCGGCAGCAGCCTC

CTGCTCCCCGCGGCCTCCAGCACTGACGCCGGCTCATACCACTGCCGGGCCCGGGACGGCCACAGTGCCA

GTGGCCCCTCTTCGCCAGCTGTTCTCACTGTGCTCTACCCCCCTCGACAACCAACATTCACCACCAGGCT

GGACCTTGATGCCGCTGGGGCCGGGGCTGGACGGCGAGGCCTCCTTTTGTGCCGTGTGGACAGCGACCCC

CCCGCCAGGCTGCAGCTGCTCCACAAGGACCGTGTTGTGGCCACTTCCCTGCCATCAGGGGGTGGCTGCA

GCACCTGTGGGGGCTGTTCCCCACGCATGAAGGTCACCAAAGCCCCCAACTTGCTGCGTGTGGAGATTCA

CAACCCTTTGCTGGAAGAGGAGGGCTTGTACCTCTGTGAGGCCAGCAATGCCCTGGGCAACGCCTCCACC

TCAGCCACCTTCAATGGCCAGGCCACTGTCCTGGCCATTGCACCATCACACACACTTCAGGAGGGCACAG

AAGCCAACTTGACTTGCAACGTGAGCCGGGAAGCTGCTGGCAGCCCTGCTAACTTCTCCTGGTTCCGAAA

TGGGGTGCTGTGGGCCCAGGGTCCCCTGGAGACCGTGACACTGCTGCCCGTGGCCAGAACTGATGCTGCC

CTTTACGCCTGCCGCATCCTGACTGAGGCTGGTGCCCAGCTCTCCACTCCCGTGCTCCTGAGTGTACTCT

ATCCCCCGGACCGTCCAAAGCTGTCAGCCCTCCTAGACATGGGCCAGGGCCACATGGCTCTGTTCATCTG

CACTGTGGACAGCCGCCCCCTGGCCTTGCTGGCCTTGTTCCATGGGGAGCACCTCCTGGCCACCAGCCTG

GGTCCCCAGGTCCCATCCCATGGTCGGTTCCAGGCTAAAGCTGAGGCCAACTCCCTGAAGTTAGAGGTCC

GAGAACTGGGCCTTGGGGACTCTGGCAGCTACCGCTGTGAGGCCACAAATGTTCTTGGATCATCCAACAC

CTCACTCTTCTTCCAGGTCCGAGGAGCCTGGGTCCAGGTGTCACCATCACCTGAGCTCCAAGAGGGCCAG

GCTGTGGTCCTGAGCTGCCAGGTACACACAGGAGTCCCAGAGGGGACCTCATATCGTTGGTATCGGGATG

GCCAGCCCCTCCAGGAGTCGACCTCGGCCACGCTCCGCTTTGCAGCCATAACTTTGACACAAGCTGGGGC

CTATCATTGCCAAGCCCAGGCCCCAGGCTCAGCCACCACGAGCCTAGCTGCACCCATCAGCCTCCACGTG

TCCTATGCCCCACGCCACGTCACACTCACTACCCTGATGGACACAGGCCCTGGACGACTGGGCCTCCTCC

TGTGCCGTGTGGACAGTGACCCTCCGGCCCAGCTGCGGCTGCTCCACGGGGATCGCCTTGTGGCCTCCAC

CCTACAAGGTGTGGGGGGACCCGAAGGCAGCTCTCCCAGGCTGCATGTGGCTGTGGCCCCCAACACACTG

CGTCTGGAGATCCACGGGGCTATGCTGGAGGATGAGGGTGTCTATATCTGTGAGGCCTCCAACACCCTGG

GCCAGGCCTCGGCCTCAGCTGACTTCGACGCTCAAGCTGTGAATGTGCAGGTGTGGCCCGGGGCTACCGT

GCGGGAGGGGCAGCTGGTGAACCTGACCTGCCTTGTGTGGACCACTCACCCGGCCCAGCTCACCTACACA

TGGTACCAGGATGGGCAGCAGCGCCTGGATGCCCACTCCATCCCCCTGCCCAACGTCACAGTCAGGGATG

CCACCTCCTACCGCTGCGGTGTGGGCCCCCCTGGTCGGGCACCCCGCCTCTCCAGACCTATCACCTTGGA

CGTCCTCTACGCGCCCCGCAACCTGCGCCTGACCTACCTCCTGGAGAGCCATGGCGGGCAGCTGGCCCTG

GTACTGTGCACTGTGGACAGCCGCCCGCCCGCCCAGCTGGCCCTCAGCCACGCCGGTCGCCTCTTGGCCT

CCTCGACAGCAGCCTCTGTCCCCAACACCCTGCGCCTGGAGCTGCGAGGGCCACAGCCCAGGGATGAGGG

TTTCTACAGCTGCTCTGCCCGCAGCCCTCTGGGCCAGGCCAACACGTCCCTGGAGCTGCGGCTGGAGGGT

GTGCGGGTGATCCTGGCTCCGGAGGCTGCCGTGCCTGAAGGTGCCCCCATCACAGTGACCTGTGCGGACC

CTGCTGCCCACGCACCCACACTCTATACTTGGTACCACAACGGTCGTTGGCTGCAGGAGGGTCCAGCTGC

CTCACTCTCATTCCTGGTGGCCACGCGGGCTCATGCAGGCGCCTACTCTTGCCAGGCCCAGGATGCCCAG

GGCACCCGCAGCTCCCGTCCTGCTGCCCTGCAAGTCCTCTATGCCCCTCAGGACGCTGTCCTGTCCTCCT

TCCGGGACTCCAGGGCCAGATCCATGGCTGTGATACAGTGCACTGTGGACAGTGAGCCACCTGCTGAGCT

GGCCCTATCTCATGATGGCAAGGTGCTGGCCACGAGCAGCGGGGTCCACAGCTTGGCATCAGGGACAGGC

CATGTCCAGGTGGCCCGAAACGCCCTACGGCTGCAGGTGCAAGATGTGCCTGCAGGTGATGACACCTATG

TTTGCACAGCCCAAAACTTGCTGGGCTCAATCAGCACCATCGGGCGGTTGCAGGTAGAAGGTGCACGCGT

GGTGGCAGAGCCTGGCCTGGACGTGCCTGAGGGCGCTGCCCTGAACCTCAGCTGCCGCCTCCTGGGTGGC

CCTGGGCCTGTGGGCAACTCCACCTTTGCATGGTTCTGGAATGACCGGCGGCTGCACGCGGAGCCTGTGC

CCACTCTCGCCTTCACCCACGTGGCTCGTGCTCAAGCTGGGATGTACCACTGCCTGGCTGAGCTCCCCAC

TGGGGCTGCTGCCTCTGCTCCAGTCATGCTCCGTGTGCTCTACCCTCCCAAGACGCCCACCATGATGGTC

TTCGTGGAGCCTGAGGGTGGCCTCCGGGGCATCCTGGATTGCCGAGTGGACAGCGAGCCGCTCGCCAGCC

TGACTCTCCACCTTGGCAGTCGACTGGTGGCCTCCAGTCAGCCCCAGGGTGCTCCTGCAGAGCCACACAT

CCATGTCCTGGCTTCCCCCAATGCCCTGAGGGTGGACATCGAGGCGCTGAGGCCCAGCGACCAAGGGGAA

TACATCTGTTCTGCCTCAAATGTCCTGGGCTCTGCCTCTACCTCCACCTACTTTGGGGTCAGAGCCCTGC

ACCGCCTGCATCAGTTCCAGCAGCTGCTCTGGGTCCTGGGACTGCTGGTGGGCCTCCTGCTCCTGCTGTT

GGGCCTGGGGGCCTGCTACACCTGGAGAAGGAGGCGTGTTTGTAAGCAGAGCATGGGCGAGAATTCGGTG

GAGATGGCTTTTCAGAAAGAGACCACGCAGCTCATTGATCCTGATGCAGCCACATGTGAGACCTCAACCT

GTGCCCCACCCCTGGGCTGA

 

Formulation: pre-packaged viral particles in the conditional medium (serum-free) from HEK293 cells (typical titer 10⁶ - 10⁷ IFU/ml)

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Important Safety Information: With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.

 

Transduction Protocol

 

Formulation: pre-packaged viral particles in the conditional medium (serum-free) from HEK293 cells (typical titer 10⁶ - 10⁷ IFU/ml)

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Important Safety Information: With the safety features in place, our lentiviral vectors and viral particles can be employed in standard Biosafety Level 2 tissue culture facilities and should be treated with the same level of caution as any other potentially infectious agent. Any investigator who purchases our lentiviral/retroviral products & services is responsible for following Biosafety Level 2 requirements on the handling of viral particles. For more information on Biosafety Level 2 agents and practices, please refer to NIH’s “Biosafety Considerations for Research with Lentiviral Vectors”.

 

Storage

 

The product is shipped at 4°C for immediate use or with dry ice.  Upon receipt, centrifuge the vial briefly before opening.  Store at –80°C or lower and the product is stable for 3 months.  Avoid repeated freeze-thaw cycles.

 

 

The product should be employed in a Biosafety Level 2 tissue culture facility.

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.